Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-28T03:24:13.718Z Has data issue: false hasContentIssue false
  • English
  • Français

Interferon alpha-2b as adjuvant treatment of recurrent respiratory papillomatosis in Cuba: National Programme (1994–1999 report)

Published online by Cambridge University Press:  08 March 2006

Hugo Nodarse-Cuní ,
Nora Iznaga-Marín ,
Ditza Viera-Alvarez ,
Hortensia Rodríguez-Gómez ,
Héctor Fernández-Fernández ,
Yazmín Blanco-López ,
Carmen Viada-González ,
Pedro López-Saura  and
Cuban Group for the Study of Interferon in Recurrent Respiratory Papillomatosis
Hugo Nodarse-Cuní
Affiliation:
Centro de Investigaciones Biológicas, La Habana, Cuba.
Nora Iznaga-Marín
Affiliation:
The Hospital Universitario ‘Calixto García’, La Habana, Cuba.
Ditza Viera-Alvarez
Affiliation:
The Hospital Pediátrico ‘Juan Manuel Márquez’, La Habana, Cuba.
Hortensia Rodríguez-Gómez
Affiliation:
The Hospital Pediátrico ‘William Soler’, La Habana, Cuba.
Héctor Fernández-Fernández
Affiliation:
The Hospital Pediátrico Sur, Santiago de Cuba, La Habana, Cuba.
Yazmín Blanco-López
Affiliation:
Centro Nacional Coordinador de Ensayos Clínicos, La Habana, Cuba.
Carmen Viada-González
Affiliation:
Centro Nacional Coordinador de Ensayos Clínicos, La Habana, Cuba.
Pedro López-Saura
Affiliation:
Centro de Investigaciones Biológicas, La Habana, Cuba.
Get access Rights & Permissions [Opens in a new window]

Abstract

Respiratory papillomatosis is a life-spoiling disease due to its high recurrence rate. Interferon (IFN) alpha-2b treatment, adjuvant to surgery, was assessed for its contribution to disease control and patient quality of life improvement. One hundred and sixty-nine patients (85 children and 84 adults) were included after surgical removal of the lesions followed by intramuscular IFN alpha-2b (Heberon alfa R, Heber Biotec), starting with 105 IU/Kg weight in children or 6 × 106 IU in adults, three times per week. The dose was reduced monthly, if no relapses occurred, until a monthly maintenance with 5 × 104 IU/Kg of weight in children or 3 × 106 IU in adults up to two years. In case of relapse, it was surgically removed and the patient returned to the higher dose level. The relapse frequency decreased significantly in 77 per cent (69/90) of the recurrent patients both in children (34/46, 74 per cent) and adults (35/44, 79 per cent). Among patients included after their first papilloma, 67 per cent (44/66) had complete (no relapses) or partial (only one relapse) responses (children: 15/33, 45 per cent; adults 29/33, 88 per cent). One hundred and eighteen patients (73 per cent) concluded the treatment without lesions (children: 58 per cent; adults 82 per cent), while the rest showed a significant reduction in the number and size of lesions. IFN was well tolerated. Sixty-two patients (38 per cent) did not have adverse events. The main adverse reactions were fever (59 per cent), chills (24 per cent), arthralgias and myalgias (14 per cent) and headache (10 per cent). One patient developed anti-IFN alpha neutralizing antibodies and became resistant to treatment with recombinant IFN alpha-2b; he responded to natural leucocyte IFN alpha. Treatment with IFN alpha-2b, as an adjuvant to surgery represents a favourable and safe therapeutic alternative for patients with recurrent respiratory papillomatosis.

Keywords

IFN Alpha-2bRespiratory Tract DiseasesPapillomaLaryngeal DiseasesSurgery
Type
Research Article
Information
The Journal of Laryngology & Otology , Volume 118 , Issue 9 , September 2004 , pp. 681 - 687
Copyright
© 2004 Royal Society of Medicine Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)